Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907881 | 0.73 | CA12 (0.40) | CA12CA1CA2CA9CA4 | |
| SCHEMBL15966047 | 0.70 | METAP2 (0.36) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL18729469 | 0.67 | KMT2A (0.38) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL4896788 | 0.66 | CA9 (0.45) | CA12CA9 | |
| SCHEMBL3150794 | 0.65 | MEN1 (0.37) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL10577326 | 0.64 | GAA (0.40) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL1622053 | 0.64 | NOS2 (0.47) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL460768 | 0.64 | GAA (0.44) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL8558399 | 0.62 | — | — | |
| SCHEMBL3541084 | 0.62 | MEN1 (0.34) | CA12CA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | claimed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | claimed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20230131668-A1 | HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-04-27 | — | — | US | disclosed |
| EP-4103191-A1 | HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | FIREMENICH INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2021163513-A1 | HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-19 | — | — | WO | disclosed |
| CN-107365319-B | Modulation of chemosensory receptors and ligands associated therewith | 弗门尼舍公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-106107406-B | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | 弗门尼舍公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2019-07-11 | — | — | US | disclosed |
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148580-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2005-07-07 | — | — | US | disclosed |
| US-6861421-B2 | Nociceptin analogs | EURO-CELTIQUE S.A (LU) | 2005-03-01 | — | — | US | disclosed |
| EP-1286992-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087881-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2001-11-22 | — | — | WO | disclosed |
| US-5929072-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| US-4189572-A | Preparation of 1H-Benzo (2,1,3)thiadiazine-3,4-dihydro-2,2-dioxides | THE DOW CHEMICAL COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | CA12 1128/4885CA1 2518/4885CA2 1888/4885 |
| US-20050148580-A1 | Nociceptin analogs | OPRL1, OPRK1, NPBWR1 | CA12 3793/4885CA1 3527/4885CA2 3512/4885 |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | CA12 1128/4885CA1 2518/4885CA2 1888/4885 |
| US-20230131668-A1 | HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS | HSF1, HSPH1, HSPA2 | CA12 4810/4885CA1 4235/4885CA2 4485/4885 |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | CA12 1128/4885CA1 2518/4885CA2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.